The AI Landscape in Life Sciences
Distinguish the three kinds of AI you'll meet in life-science work, see where each shows up across the product lifecycle, and learn the four fluency competencies this course builds.
One Word, Three Very Different Things
“We’re using AI” can mean almost anything in a life-science company. A protein-structure model, a chatbot that drafts a clinical study report section, and a vision system inspecting vials on a fill line are all “AI,” but they fail differently, are regulated differently, and need different kinds of checking.
Before you decide how much to trust any tool, sort it into one of three groups.
1. Scientific and predictive models
Purpose-built models trained on scientific data to make a specific prediction:
- Structure prediction (for example, AlphaFold and its successors) estimates how a protein folds or how molecules bind.
- Property prediction scores candidate molecules for solubility, toxicity, or binding affinity.
- Image analysis counts cells, segments tissue, or flags anomalies in histology slides.
- Operational prediction forecasts trial enrollment, equipment failure, or batch yield.
These models usually output a number, a structure, or a classification, often with a confidence score. Their main risk is being used outside the conditions they were trained and validated on.
2. General-purpose generative assistants
Large language models (LLMs) such as Claude, ChatGPT, Gemini, or Copilot, used to read, summarize, draft, translate, or write code. They’re flexible and fluent, which is exactly the problem: they produce confident text whether or not it’s true. Most of this course focuses here, because these are the tools most professionals now use daily, often without any formal process.
3. AI embedded in regulated systems
AI features built into validated systems: a quality-management system that suggests deviation root causes, a pharmacovigilance platform that auto-codes adverse events, an electronic data capture system that flags data anomalies, or a visual-inspection system on a manufacturing line. These sit inside GxP processes (Good Laboratory, Clinical, Manufacturing, and Pharmacovigilance Practice), so they carry validation, data-integrity, and audit-trail obligations that a stand-alone chatbot does not.
Common mistake: “It’s a validated system, so the new AI feature is validated too.”
A vendor’s release notes are not your validation. When AI is added to a GxP system, your organization still has to assess the feature against your intended use, document that assessment, and control changes to it. Ask your quality unit before turning on any new AI feature in a validated system.
Where AI Shows Up Across the Lifecycle
- 1 Discovery
Targets, molecules, literature
- 2 Preclinical
Image analysis, tox prediction
- 3 Clinical
Protocols, recruitment, data review
- 4 Regulatory
Submissions, labeling, queries
- 5 Manufacturing
Inspection, process control
- 6 Post-market
Safety, medical information
The further right you move, the closer AI output gets to a patient and the heavier the regulatory obligations become. A wrong literature summary in discovery wastes time. A wrong adverse-event assessment in post-market safety can delay a safety signal.
The Four Competencies
This course is organized around the 4D AI Fluency Framework:
- Delegation: deciding which tasks AI should do, which it should assist with, and which it should stay out of, given the scientific, patient, and regulatory stakes.
- Description: giving AI the context, constraints, and format it needs, without giving it data it shouldn’t have.
- Discernment: checking AI output against primary sources, raw data, and your own expertise.
- Diligence: owning the result. Documenting AI use where it matters, following SOPs, and being transparent with colleagues, regulators, journals, and patients.
The four competencies form a loop. What you learn while checking output (Discernment) changes what you delegate next time.
How This Course Is Organized
| Module | Focus |
|---|---|
| 1. Foundations | The AI landscape and how AI fails in science |
| 2. Delegation and data protection | Risk-tiered delegation; confidential, patient, and proprietary data |
| 3. Research and discovery | Literature, writing, data analysis, and discovery models |
| 4. Clinical development | Trial documents, operations, and pharmacovigilance |
| 5. Regulatory and quality | GxP, data integrity, validation, and the regulatory landscape |
| 6. Communication and accountability | Medical affairs, commercial content, and your 90-day plan |
You don’t need to work in every function. Each module stands on its own after Modules 1 and 2, so skip ahead to the parts of the lifecycle you touch.
List every AI tool you used, or that touched your work, in the last two weeks. For each one, note:
- Which of the three groups it falls in (scientific model, generative assistant, embedded in a regulated system).
- Whether it’s an approved tool at your organization, and how you know.
- Whether its output fed into anything GxP, anything submitted externally, or anything a patient will see.
Keep this list. You’ll use it again in Module 2 and in your 90-day plan.
1. A vendor adds an AI root-cause suggestion feature to your validated quality-management system. What's the right first step?
New AI functionality in a GxP system is a change. Your organization must assess it for its intended use and manage it under change control.
2. What is the main risk of scientific and predictive models such as structure or property predictors?
Purpose-built models can be very good inside their training domain and unreliable outside it. Know the domain before you trust the number.
3. Which competency covers documenting AI use and being transparent with regulators and journals?
Diligence is about accountability: documentation, transparency, and owning what you put your name to.
Up Next
Before deciding what to delegate, you need to know how AI goes wrong in scientific work. The next lesson covers the failure modes that matter most.